Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
July 08, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
June 24, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
June 16, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate at the LifeSci Partners Genetic Medicines Summit 2021
June 14, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Frontiers in Immunology Publication Showcasing the Enhanced Hepatic Tolerogenic Potential of ImmTOR™
June 01, 2021 08:00 ET
|
Selecta Biosciences, Inc.
– Data demonstrate that ImmTOR enhances the tolerogenic environment in the liver– – ImmTOR data show induction of a tolerogenic phenotype in all major hepatic antigen presenting cell populations and...
Selecta Biosciences to Participate at the Jefferies Virtual Healthcare Conference
May 25, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 08:00 ET
|
Selecta Biosciences, Inc.
SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021SEL-212 enrollment on track with topline data from DISSOLVE phase 3 program expected in...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update
May 06, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 29, 2021 16:15 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
April 29, 2021 08:30 ET
|
Selecta Biosciences, Inc.
– Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains...